Ricerc@Sapienza

Several studies have been performed with the aim of identifying drugs able in inhibiting Epithelial-Mesenchymal Transition (EMT), chiefly by blocking PI3K/Akt pathway. We have already demonstrated that treatment with myo-Inositol at the pharmacological dose can block EMT in breast cancer cells by downregulating PI3K/Akt and inducing changes in cytoskeletal architecture. Herewith, we investigated the mechanism of action of myo-inositol in both highly (MDA-MB-231) and low (MCF-7) invasive human breast cancer cells.

Background: Several researches have been performed with the aim of identifying drugs able in blocking PI3K/Akt pathway. We have already demonstrated that myo-Inositol (myo-Ins) treatment can block EMT in breast cancer cells by downregulating PI3K/Akt and inducing changes in cytoskeletal architecture. Aim: Herein, we set our experiments to investigate migration/invasiveness inhibition though in vitro and in vivo models upon myo-Ins administration.